
[Cancer Research 60, 799-802, February 15, 2000]
© 2000 American Association for Cancer Research
Detection of Gene Amplification by Genomic Hybridization to cDNA Microarrays
Mervi A. Heiskanen,
Michael L. Bittner,
Yidong Chen,
Javed Khan,
Karl E. Adler,
Jeffrey M. Trent and
Paul S. Meltzer1
Cancer Genetics Branch, National Human Genome Research Institute, NIH, Bethesda, Maryland 20892 [M. A. H., M. L. B., Y. C., J. K., J. M. T., P. S. M.], and DuPont NEN Life Science Products, Inc., Boston, Massachusetts 02118 [K. E. A.]
 |
ABSTRACT
|
|---|
Gene amplification is one of the major mechanisms of oncogene activation
in tumorigenesis. To facilitate the identification of genes mapping to
amplified regions, we have used a technique based on the hybridization
of total genomic DNA to cDNA microarrays. To aid detection of the weak
signals generated in this complex hybridization, we have used a
tyramide-based technique that allows amplification of a fluorescent
signal up to 1000-fold. Dilution experiment suggests that
amplifications of 5-fold and higher can be detected by this approach.
The technique was validated using cancer cell lines with several known
gene amplifications, such as those affecting MYC, MYCN,
ERBB2, and CDK4. In addition to the detection of
the known amplifications, we identified a novel amplified gene,
ZNF133, in the neuroblastoma cell line NGP.
Hybridization of NGP cDNA on an identical array also revealed over
expression of ZNF133. Parallel analysis of genomic DNA
for copy number and cDNA for expression now provides rapid approach to
the identification of amplified genes and chromosomal regions in tumor
cells.
 |
Introduction
|
|---|
Chromosomal anomalies resulting in gain or loss of genetic
material are frequent in tumor cells. These changes may result in
alterations in the level of expression of numerous genes. Indeed, gene
amplification is one of the most common mechanisms for oncogene
activation in solid tumors. It is therefore of considerable interest to
develop strategies for identifying amplified genes and determining
their expression levels in cancer. Until recently, gene amplification
has been detected by DNA-based techniques (PCR or Southern blot) or by
molecular cytogenetic techniques
(FISH2
with gene-specific probes). These techniques are inherently restricted
to the analysis of previously known amplified genes. In contrast,
genome-wide scanning of amplified chromosomal regions with CGH
(1)
has become an important technique for the detection of
amplified regions in tumor DNA. However, CGH has limited sensitivity
and resolution (2)
. In addition, the identification of the
specific target gene within an amplicon defined by CGH remains daunting
because of the limited mapping resolution provided by the metaphase
chromosomes.
DNA microarray technology offers the possibility to replace the target
metaphase chromosomes with arrays of DNA clones on a microscope slide.
Arrayed fragments of cloned genomic DNAs have been used for this
purpose (3
, 4)
. These CGH microarray techniques allow
amplification detection on the resolution level equal to the length of
the arrayed DNA clones (
100 kb). Genomic microarrays have been
applied to amplicon mapping (4)
, but the technique can
also be used for rapid surveys of known copy number alterations in
tumor samples. In principle, a further increase in resolution can be
obtained by using arrayed cDNAs rather than genomic DNA. This approach
is particularly attractive because of the availability of thousands of
accurately mapped cDNAs. Furthermore, expression analysis can be
carried out in parallel on the same microarray slides, enabling a
correlation of copy number and gene expression. However, signal
intensities in genomic hybridizations are proportional to the length of
the target DNA (4)
. Reproducibly achieving a measurable
hybridization signal from total genomic DNA hybridized to targets
covering only 0.52 kb is difficult and requires a signal detection
system with high sensitivity and low background. An approach for CGH on
cDNA microarrays was reported recently by Pollack et al.
(5)
using directly labeled fluorochrome probes. We report
here an alternative technique that also uses cDNA arrays prepared for
expression studies. Our results indicate that this technique is
reproducibly capable of detecting gene amplifications of 5-fold or
higher. Finally, the suitability of the technique for genome-wide
screening of amplified and overexpressed genes was tested by
hybridizing both genomic neuroblastoma DNA and mRNA on a microarray
containing 1400 genes. In addition to known amplifications on 2p and
12q, a previously unrecognized amplicon on 20p containing a zinc finger
gene (ZNF133) was identified.
 |
Materials and Methods
|
|---|
Preparation of cDNA Microarrays
cDNA microarrays were prepared as described previously
(6)
. To validate the technique, microarrays containing 14
different cDNAs representing genes known to be amplified in cancer cell
lines were printed (CDK4, MDM2, OS4, OS9, MYCN, MYC, MYCL, EGFR,
AKT2, ERBB2, AIB1, IGFR1, CLND, and SAS.) For screening
of unknown amplified genes, an array containing 1400 cDNAs was used
(6)
.
Genomic Hybridization, Signal Detection, and Amplification
Total genomic DNA was labeled with biotin by nick translation
for 2.5 h at 15°C. The fragment size of the labeled probe
was between 400-2000 bp. Unincorporated nucleotides were removed
using Micro Bio-Spin 6 Chromatography Columns (Bio-Rad, Hercules,
CA). Hybridization mixture (10 µl) was composed of 1 µg of
biotinylated probe, 40 µg of Cot-1 DNA (Life Technologies, Inc.,
Rockville, MD) and 8 µg of poly dA in 3X SSC (0.15 M
NaCl, 0.015 M sodium citrate)/0.01% SDS. After
denaturation, the hybridization mixture was added on the slide and
hybridized in a hybridization chamber at 65°C over night. Slides were
washed in 0.5X SSC/0.01% SDS, 0.06x SSC/0.01% SDS, and 0.06X SSC at
room temperature for 5 min each. Hybridization signals were developed
using tyramide reagents (Renaissance TSA-indirect ISH; DuPont NEN Life
Science Products). Slides were blocked using 10% goat serum in TN
blocking buffer [0.1 M Tris (pH 7.6), 0.15
M NaCl]. Hybridization was detected by first incubating
the slide with streptavidin conjugated with horseradish peroxidase
(1:100 in TN-10% goat serum), followed by signal amplification with
biotinyl tyramide (1:50 in reaction buffer with 1% blocking reagent).
Biotinyl tyramide was detected by streptavidin conjugated with Cy3
(1:500 in TN-10% goat serum). Between and after incubations, slides
were washed with TNT buffer [0.1 M Tris-HCl (pH 7.5), 0.15
M NaCl, and 0.05% Tween 20] 3 x 1 min.
All of the incubations and washings were done at room temperature.
cDNA Hybridization for Gene Expression Analysis
Hybridization of NGP cDNA on a microarray containing 1400 genes
has been described in detail previously (6)
.
Image Analysis and Outlier Detection
Amplification Intensity.
A gray scale fluorescent image for each microarray slide was obtained
from a confocal scanning microscope. DNA target segmentation and signal
detection methods were then used to determine the actual target
regions, average signal intensities, and local background intensities
(7)
. The background subtracted average signal intensity
was reported as the hybridization intensity.
Fold Increase.
An iterative amplification intensity outlier detection algorithm was
then applied as follows:
(a) Assuming there were N cDNA targets presented
in microarray slides, we first sorted all intensities
Ik in ascending order,
I1 > I2 >... > IN. We then partitioned intensities into two
groups (I1, ... ,
INm) and (INm+1,
... , IN). Initially, we chose
m = N/2.
(b) The discordance test (for a single outlier in a normal
sample with m and s unknown) was performed for
the first amplification intensity from the second group:
where
and
and
b is the SD of local background at
the same location of IN-m+1. The test statistic
T can be converted to Students t test with
N - 2 degrees of freedom [Barnett and Lewis
(8)
]. As an example, the critical value for n = 40 and
= 1% discordance, t must be >3.24.
3) If the IN-m+1 was not an outlier, let
m
m + 1, and then repeat step 2
until the first outlier intensity was obtained.
If at least one outlier was obtained, the amplification intensities
were partitioned into two groups: (a) negative targets that
exhibit no signification amplification intensities; and (b)
positive targets of which intensities were statistically different from
those from the negative group. The fold increase
rk was then calculated for all genes in the
positive target group (IN-m+1,
,
IN) by rk =
Ik/µ1 for
k = N - m + 1,
, N.
P Value.
To further assess the significance of each reported positive
amplification intensity, P from the aforementioned
discordance t test statistic (8)
can be
calculated.
In Situ Hybridization
A BAC clone specific for ZNF133 (169o05) was screened
from a human BAC library (Research Genetics, Inc. Huntsville, AL) using
primers specific for marker
W118789.3
The probe was labeled with Spectrum Orange by random priming (BioPrime
DNA Labeling System; Life Technologies, Inc.). FISH-based copy number
determination for the ZNF133 region included a
fluorescein-labeled satellite probe for chromosome 20 (Oncor).
 |
Results
|
|---|
We initially tested tyramide signal detection on microarrays
containing 14 genes amplified in various cancers by hybridizing genomic
DNA from a neuroblastoma with a 100-fold amplification of the
MYCN oncogene (9)
. MYCN was
specifically identified as an outlier in this hybridization. To
determine the sensitivity of the procedure, tumor DNA was diluted with
normal DNA prior to labeling. Seven dilutions ranging from 100 to 2%
of NGP DNA were hybridized to cDNA microarrays (Fig. 1)
. Four normal control hybridizations were also included in the
experiment. The MYCN signal intensities were normalized to
the average signal intensity of all of the nonamplified spots on the
array. The results revealed a decrease in the MYCN cDNA
signal intensity with dilution of the NGP DNA. In the hybridization
containing 2% NGP DNA, the MYCN signal intensity was
increased 2.5-fold relative to the nonamplified spots, indicating that
amplifications of
5-fold can be detected. In this experiment, the
signal intensities were not directly proportional to the gene copy
number. The lower signal intensity of the undiluted NGP hybridization
compared with the first dilution (75% of NGP) is likely explainable by
the increased self annealing of the probe, which limits the
hybridization of the probe to the target cDNA.

View larger version (62K):
[in this window]
[in a new window]
|
Fig. 1. Dilution of NGP neuroblastoma cell line DNA with normal
DNA. The X-axis shows the different dilutions of tumor
DNA, from 100% of NGP (representing 100-fold amplification of
MYCN) down to 2% of NGP DNA in the labeling reaction.
The MYCN ratio on the Y-axis was
calculated by dividing the MYCN signal intensity with
the average intensity of all of the nonpositive spots on the array.
Four hybridizations of the same normal DNA used for NGP dilution were
included in the experiment. The average ratio of the
MYCN spot to the other spots on the array in four normal
control hybridizations was 0.66 (SD, 0.70).
|
|
We then extended this technique to other cancer cell lines with known
gene amplifications (Refs. 10, 11, 12
; Table 1
; Fig. 2
). Amplified genes were identified according to the distribution of
signal intensities, and a fold change in signal intensity was
calculated by dividing the intensity of any particular spot by the
average intensity of all of the nonamplified spots on the array. By
these criteria, 11 of 13 known gene amplifications were detected. The
amplification level of identified genes ranged from 5-fold
(ERBB2) up to 100-fold (MYCN). Only two
previously recognized gene amplifications were not detected by this
method were OS9 in NGP and MYC in BT474. Although
the NGP OS9 signal intensity was 2-fold above the average,
this result did not meet our criteria for statistical significance. The
level of MYC amplification in BT474 has been determined to
be only 3.5-fold by interphase
FISH.4
However, ERBB2 amplification was detected in BT474
(6-fold4
) as well as in SKBR3
(5-fold4
). These results correlate well with the
NGP dilution experiment (Fig. 1)
, which suggested that the sensitivity
of detection is
5-fold.

View larger version (51K):
[in this window]
[in a new window]
|
Fig. 2. Two examples of the genomic hybridization on cDNA arrays.
A, high-level amplification of MYC in
colon cancer cell line Colo320. Signal intensity of MYC
is 16-fold higher than the nonamplified signal intensity in this
hybridization. B, hybridization of breast cancer cell line
SKBR3. In this hybridization, the signal intensity ratios were 9-fold
for MYC and 22-fold for ERBB2. The level
of ERBB2 amplification has been determined to be 6-fold
and MYC amplification 32-fold by interphase
FISH.4 The grid indicates the pattern of cDNAs printed on
the microarray.
|
|
To determine whether previously unknown amplification could be
identified this technique, we hybridized NGP genomic DNA to a 1400
element cDNA microarray. In addition to the known amplified genes, a
novel gene amplification was identified in this experiment (Fig. 3)
. The signal intensity of an expressed sequence tag representing
ZNF133 was observed to be significantly increased (8-fold
over the mean). ZNF133 has been mapped previously to 20p11.2
by in situ hybridization (13)
. CGH of NGP on
metaphase chromosomes also indicated the amplification of this
chromosomal region (data not shown). To verify the amplification, a
ZNF133 BAC clone was hybridized on NGP cells in
situ. The signal copy number in interphase nuclei was
heterogeneous, ranging from 2 copies up to 22 copies of
ZNF133 per cell. The average copy number calculated from 50
cells was 6.6. In contrast, two copies of the chromosome 20 centromere
reference probe were detected in all nuclei.

View larger version (38K):
[in this window]
[in a new window]
|
Fig. 3. Amplification and overexpression of zinc finger gene
ZNF133 in NGP neuroblastoma cell line. A,
section of a 1400-element cDNA microarray containing
ZNF133 (boxed) after hybridization of NGP
total genomic DNA and tyramide detection. The intense
ZNF133 signal (8-fold) suggests amplification of
ZNF133. B, corresponding section of an
identical microarray after cDNA hybridization with NGP cDNA
(pseudocolor red) and normal fibroblast DNA
(pseudocolor green). The red:green ratio of 3.37 for
ZNF133 (boxed) shows that the amplified copies of
ZNF133 are highly overexpressed. C,
interphase FISH on NGP confirming amplification of
ZNF133 (red) relative to a chromosome 20
satellite (green).
|
|
In two-color hybridization of NGP cDNA (red) relative to normal
fibroblast cDNA (green), the red:green ratio of the ZNF133
was 3.4, indicating a significant increase in expression of this
amplified gene relative to the reference probe (6)
. This
demonstrates the ability to perform both expression and copy number
analysis on the same set of microarrays.
 |
Discussion
|
|---|
Compared with the previously published CGH microarray techniques
where genomic DNA is hybridized on arrayed genomic clones (3
, 4)
, hybridization on cDNA arrays offers significant advantages.
The most important is the possibility to directly identify amplified
genes rather than amplified genomic regions. Another advantage is the
ability to do expression studies on the same arrays using the standard
cDNA microarray approach. Finally, thousands of mapped cDNAs are
readily available, which facilitates amplicon mapping and
identification of new cancer genes.
The complexity of the probe and the small sizes of the arrayed target
cDNAs (0.52 kb) place high demands on the sensitivity of the system.
Using tyramide-based signal amplification (14)
, it is
possible to enhance fluorescent signals up to 1000-fold. Deposition of
biotin tyramides has been applied previously for the amplification of
in situ hybridization signals (15)
. We show
here that the peroxidase-mediated deposition of biotin tyramide can
also be applied on high sensitivity detection of gene amplification on
cDNA microarrays to detect gene amplifications of 5-fold or greater.
Although we have tested the addition of a second tyramide reagent to
provide two-color CGH, there was excessive cross-talk between tyramide
reagents under the conditions necessary for genomic hybridization.
Nonetheless, the tyramide method described here consistently generates
significant signal intensities necessary for a screening technique for
gene amplification.
In the hybridization of NGP DNA to a 1400-element cDNA microarray, we
identified the known 2p and 12q amplicons as well as a novel 20p
amplicon containing a zinc finger gene ZNF133. This gene
belongs to the family of Kruppel-related zinc finger genes that have
been connected with transcriptional repression (13)
.
Amplification and overexpression of ZNF133 have not been
reported previously, but the amplification of this chromosomal region
has been detected by CGH in several different types of malignancies. In
a CGH study of 58 primary gastric cancers, 20p gain was detected in
38% of cases (16)
. In chondrosarcomas, gain of 20p was
observed in 31% of the analyzed tumors (17)
. 20p
amplification has also been reported in ductal carcinoma in
situ of the breast, in bladder tumors, as well as in osteosarcoma,
ovarian cancer, adenocarcinoma of gastroesophageal junction, squamous
cell carcinoma, small cell lung cancer, and non-small cell lung cancer
(18)
. Although it is impossible to delineate the size and
genetic composition of the 20p amplicon from the small microarray used
in this study, larger arrays will provide an amplicon map at higher
density. This information should prove extremely useful for focusing
efforts to identify amplification target genes. With sufficient cDNA
density, it should prove possible to map core regions of amplification
in multiple tumor specimens. This information can then be further
correlated with expression patterns determined across the amplified
region. When integrated with the rapidly emerging human genome
sequence, this approach should greatly accelerate the discovery of
genes amplified during tumor progression.
 |
ACKNOWLEDGMENTS
|
|---|
We thank Kimberly Gayton, William Giasi, Gerald Gooden, and John
Lueders for excellent technical assistance.
 |
FOOTNOTES
|
|---|
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
1 To whom requests for reprints should be
addressed, Cancer Genetics Branch, National Human Genome Research
Institute, NIH, 49 Convent Drive, MSC 4470, Bethesda, MD 20892. 
2 The abbreviations used are: FISH, fluorescence
in situ hybridization; CGH, comparative genomic
hybridization. 
3 Internet address:
http://www.genome.wi.mit.edu. 
4 A. Kallioniemi, personal communication. 
Received 9/22/99.
Accepted 1/ 3/00.
 |
REFERENCES
|
|---|
-
Kallioniemi A., Kallioniemi O-P., Sudar D., Rutovitz D., Gray J. W., Waldman F., Pinkel D. Comparative genomic hybridization for molecular cytogenetic analysis of solid tumors. Science (Washington DC), 258: 818-821, 1992.[Abstract/Free Full Text]
-
Piper J., Rutovitz D., Sudar D., Kallioniemi A., Kallioniemi O-P., Waldman F. M., Gray J. W., Pinkel D. Computer image analysis of comparative genomic hybridization. Cytometry, 19: 10-26, 1995.[Medline]
-
Solinas-Toldo S., Lampel S., Stilgenbauer S., Nickolenko J., Benner A., Dohner H., Cremer T., Lichter P. Matrix-based comparative genomic hybridization: biochips to screen for genomic imbalances. Genes Chromosomes Cancer, 20: 399-407, 1997.[Medline]
-
Pinkel D., Segraves R., Sudar D., Clark S., Poole I., Kowbel D., Collins C., Kuo W. L., Chen C., Zhai Y., Dairkee S. H., Ljung B. M., Gray J. W., Albertson D. G. High resolution analysis of DNA copy number variation using comparative genomic hybridization to microarrays. Nat. Genet., 2: 207-211, 1998.
-
Pollack J. R., Perou C. M., Alizadeh A. A., Eisen M. B., Pergamenschikov A., Williams C. F., Jeffrey S. S., Botstein D., Brown P. O. Genome-wide analysis of DNA copy number changes using cDNA microarrays. Nat. Genet., 23: 41-46, 1999.[Medline]
-
Khan J., Simon R., Bittner M., Chen Y., Leighton S. B., Pohida T., Smith P. D., Jiang Y., Gooden G. C., Trent J. M., Meltzer P. S. Gene expression profiling of alveolar rhabdomyosarcoma with cDNA microarrays. Cancer Res., 58: 5009-5013, 1998.[Abstract/Free Full Text]
-
Chen Y., Dougherty E. R., Bittner M. L. Ratio-based decisions and the quantitative analysis of cDNA microarray images. Biomed. Optics, 2: 364-374, 1997.
-
Barnett, V., and Lewis, T., Outliers in Statistical Data, Ed. 3, p. 216. New York: John Wiley and Sons, 1994.
-
Schwap M., Varmus H. E., Bishop J. M., Grzeschik K-H., Naylor S. L., Sakaguchi A. Y., Brodeur B., Trent J. Chromosome localization in normal human cells and neuroblastomas of a gene related to C-MYC. Nature (Lond.), 308: 288-308, 1984.[Medline]
-
Dalla-Favera R., Wong-Staal F., Gallo R. C. Oncogene amplification in promyelocytic leukemia cell line HL-60 and in primary leukaemic cells of the same patient. Nature (Lond.), 299: 61-63, 1982.[Medline]
-
Alitalo K., Schwab M., Lin C. C., Varmus H. E., Bishop J. M. Homogeneously staining chromosomal regions contain amplified copes of an abundantly expressed cellular oncogene (C-MYC) in malignant neuroendocrine cells from a human colon carcinoma. Proc. Natl. Acad. Sci. USA, 80: 1707-1711, 1983.[Abstract/Free Full Text]
-
Elkahloun A., Bittner M., Hoskins K., Gemmil R., Meltzer P. Molecular cytogenetic characterization and physical mapping of 12q1315 amplification in human cancers. Genes Chromosomes Cancer, 17: 205-214, 1996.[Medline]
-
Tommerup N., Vissing H. Isolation and fine mapping of 16 novel human zinc finger-encoding cDNAs identify putative candidate genes for developmental and malignant disorders. Genomics, 27: 259-264, 1995.[Medline]
-
Bobrow M. N., Harris T. D., Shaughessy K. J., Litt G. J. Catalyzed reporter deposition, a novel method of signal amplification. Application to immunoassays. J. Immunol. Methods, 125: 279-285, 1989.[Medline]
-
Raap A. K., van de Corput M. P. C., Vervenne E. A. W., Gijlswijk R. P. M., Tanke H. J., Wiegant J. Ultrasensitive FISH using peroxidase-mediated deposition of biotin of fluorochrome tyramides. Hum. Mol. Genet., 4: 529-534, 1995.[Abstract/Free Full Text]
-
Sakakura C., Mori T., Sakabe T., Ariyama Y., Shinomiya T., Date K., Hagiwara A., Yamaguchi T., Takahashi T., Nakamura Y., Abe T., Inazawa J. Gains, losses, and amplifications of genomic materials in primary gastric cancers analyzed by comparative genomic hybridization. Genes Chromosomes Cancer, 24: 299-305, 1999.[Medline]
-
Larramendy M. L., Tarkkanen M., Valle J., Kivioja A. H., Ervasti H., Karaharju E., Salmivalli T., Elomaa I., Knuutila S. Gains, losses, and amplifications of DNA sequences evaluated by comparative genomic hybridization in chondrosarcomas. Am. J. Pathol., 150: 685-691, 1997.[Abstract]
-
Knuutila S., Bjorkqvist A-M., Autio K., Tarkkanen M., Wolf M., Monni O., Szymanska J., Larramendy M. L., Tapper J., Pere H., El-Rifai W., Hemmer S., Wasenius V-M., Vidgren V., Zhu Y. DNA copy number amplifications in human neoplasmsa review of comparative genomic hybridization studies. Am. J. Pathol., 152: 1107-1123, 1998.[Abstract]
This article has been cited by other articles:

|
 |

|
 |
 
J. J. Molenaar, M. E. Ebus, J. Koster, P. v. Sluis, C. J.M. van Noesel, R. Versteeg, and H. N. Caron
Cyclin D1 and CDK4 Activity Contribute to the Undifferentiated Phenotype in Neuroblastoma
Cancer Res.,
April 15, 2008;
68(8):
2599 - 2609.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. K Gruvberger-Saal, H. E Cunliffe, K. M Carr, and I. A Hedenfalk
Microarrays in breast cancer research and clinical practice - the future lies ahead
Endocr. Relat. Cancer,
December 1, 2006;
13(4):
1017 - 1031.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H. Ji, J. Kumm, M. Zhang, K. Farnam, K. Salari, M. Faham, J. M. Ford, and R. W. Davis
Molecular Inversion Probe Analysis of Gene Copy Alterations Reveals Distinct Categories of Colorectal Carcinoma
Cancer Res.,
August 15, 2006;
66(16):
7910 - 7919.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. Brennan, Y. Zhang, C. Leo, B. Feng, C. Cauwels, A. J. Aguirre, M. Kim, A. Protopopov, and L. Chin
High-Resolution Global Profiling of Genomic Alterations with Long Oligonucleotide Microarray
Cancer Res.,
July 15, 2004;
64(14):
4744 - 4748.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J Schoumans, B-M Anderlid, E Blennow, B T Teh, and M Nordenskjold
The performance of CGH array for the detection of cryptic constitutional chromosome imbalances
J. Med. Genet.,
March 1, 2004;
41(3):
198 - 202.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
V. Bourdon, F. Naef, P. H. Rao, V. Reuter, S. C. Mok, G. J. Bosl, S. Koul, V. V. V. S. Murty, R. S. Kucherlapati, and R. S. K. Chaganti
Genomic and Expression Analysis of the 12p11-p12 Amplicon Using EST Arrays Identifies Two Novel Amplified and Overexpressed Genes
Cancer Res.,
November 1, 2002;
62(21):
6218 - 6223.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Arcellana-Panlilio and S. M. Robbins
Cutting-edge technology: I. Global gene expression profiling using DNA microarrays
Am J Physiol Gastrointest Liver Physiol,
March 1, 2002;
282(3):
G397 - G402.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Wilhelm, J. A. Veltman, A. B. Olshen, A. N. Jain, D. H. Moore, J. C. Presti Jr., G. Kovacs, and F. M. Waldman
Array-based Comparative Genomic Hybridization for the Differential Diagnosis of Renal Cell Cancer
Cancer Res.,
February 1, 2002;
62(4):
957 - 960.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Gronda, S. Arab, B. Iafrate, H. Suzuki, and B. W. Zanke
Hematopoietic Protein Tyrosine Phosphatase Suppresses Extracellular Stimulus-Regulated Kinase Activation
Mol. Cell. Biol.,
October 15, 2001;
21(20):
6851 - 6858.
[Abstract]
[Full Text]
[PDF]
|
 |
|